Trial Profile
A Double-blind, Placebo-controlled, Dose Escalating Study to Assess the Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of ASP1941 and to Explore the Effect of ASP1941 on Urine and Blood Glucose Levels in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Jun 2014
Price :
$35
*
At a glance
- Drugs Ipragliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Astellas Pharma
- 01 Dec 2011 Results published in the Clinical Drug Investigation.
- 10 Feb 2011 New trial record